Tenaya Therapeutics approves restructuring; workforce reduction extends cash runway to H2 2026

Tenaya Therapeutics, Inc.

Restructuring focuses resources on TN-201 (MyPEAK-1) and TN-401 (RIDGE-1) gene therapy trials.
Workforce reduction implemented; no expected impact on enrollment milestones or data readouts.
Estimated severance and health benefit charges of $1.6M–$2.7M, substantially all by Q3 2025.
Cash runway extended into second half of 2026 via cost-containment measures.
Sufficient drug product produced for ongoing trials; manufacturing for pivotal studies continues.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.